Flumazenil

( DrugBank: Flumazenil / KEGG DRUG: Flumazenil )


5 diseases
IDDisease name (Link within this page)Number of trials
6Parkinson disease3
13Multiple sclerosis/Neuromyelitis optica4
17Multiple system atrophy1
IDDisease name (Link within this page)Number of trials
18Spinocerebellar degeneration1
206Fragile X syndrome2

6. Parkinson disease


Clinical trials : 2,817 / Drugs : 2,606 - (DrugBank : 348) / Drug target genes : 185 - Drug target pathways : 205 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

13. Multiple sclerosis/Neuromyelitis optica


Clinical trials : 3,898 / Drugs : 2,785 - (DrugBank : 360) / Drug target genes : 265 - Drug target pathways : 239 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

17. Multiple system atrophy


Clinical trials : 171 / Drugs : 202 - (DrugBank : 51) / Drug target genes : 58 - Drug target pathways : 114 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

18. Spinocerebellar degeneration


Clinical trials : 144 / Drugs : 174 - (DrugBank : 40) / Drug target genes : 50 - Drug target pathways : 75 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

206. Fragile X syndrome


Clinical trials : 124 / Drugs : 103 - (DrugBank : 35) / Drug target genes : 58 - Drug target pathways : 84 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries